ENDRA Life Sciences Inc. Common Stock (NDRA) is a publicly traded Healthcare sector company. As of November 16, 2026, NDRA trades at $4.35 with a market cap of $6.61M and a P/E ratio of -0.69. NDRA moved +0.00% today. Year to date, NDRA is +3.26%; over the trailing twelve months it is -33.88%. Its 52-week range spans $2.90 to $11.96. Rallies surfaces NDRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ENDRA Life Sciences amends merger deal with ASP Isotopes affiliate, drops classified board requirement: ENDRA Life Sciences amended its planned merger with ASP Isotopes unit Noble Africa, resetting a cash closing condition to $3,800,002.59 and revising governance and warrant terms. Renergen’s borrowing capacity under an ASPI term loan facility increased to $120 million, with a further increase to $200 million contemplated by closing.
| Metric | Value |
|---|---|
| Price | $4.35 |
| Market Cap | $6.61M |
| P/E Ratio | -0.69 |
| EPS | $-8.93 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.96 |
| 52-Week Low | $2.90 |
| Volume | 4.47K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-7.03M |
| Gross Margin | 0.00% |
NDRA analyst coverage data. Average price target: $0.00.